» Articles » PMID: 15326109

Urokinase Anchors UPAR to the Actin Cytoskeleton

Overview
Specialty Ophthalmology
Date 2004 Aug 25
PMID 15326109
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate the expression and localization of urokinase plasminogen activator (uPA) and its receptor (uPAR) and their interaction with the actin cytoskeleton in human corneal fibroblasts.

Methods: Primary cultured human corneal fibroblasts were exposed to exogenous uPA to investigate its effect on the distribution of uPAR under resting conditions and in a scrape-wound model. Fluorescence microscopy, immunolocalization, immunoprecipitation, and the actin depolymerizing drug cytochalasin D were used to evaluate uPAR's interaction with the actin cytoskeleton.

Results: uPA/uPAR was immunodetected in large (200 microm2) aggregates devoid of detectable F-actin. However, when uPA was added to corneal fibroblasts before fixation, a dynamic association between uPAR and the actin cytoskeleton was revealed: the uPA/uPAR complex was immunodetected throughout the surface of the plasma membrane in the form of dispersed small aggregates (0.05 microm2). Association of uPAR with actin stress fibers was visualized when FITC-labeled uPA was added to the cells. This codistribution of uPA/uPAR and actin was not detected when the cells were pretreated with the actin-depolymerizing drug, cytochalasin D. uPAR was found also in focal adhesions, the termination points of F-actin, where it colocalized with the integrin alphavbeta3 in cells migrating into a scrape wound. Coimmunoprecipitation experiments confirmed the physical association of uPAR with alphavbeta3 in fibroblasts.

Conclusions: The authors propose that uPA/uPAR ligation anchors the complex to the actin cytoskeleton and is a part of the mechanism responsible for uPA-induced cell migration in fibroblasts.

Citing Articles

USP10 Targeted Self-Deliverable siRNA to Prevent Scarring in the Cornea.

Boumil E, Castro N, Phillips A, Chatterton J, McCauley S, Wolfson A Mol Ther Nucleic Acids. 2020; 21:1029-1043.

PMID: 32829179 PMC: 7452140. DOI: 10.1016/j.omtn.2020.07.032.


Urokinase-type plasminogen activator (uPA) protects the tripartite synapse in the ischemic brain via ezrin-mediated formation of peripheral astrocytic processes.

Diaz A, Merino P, Manrique L, Cheng L, Yepes M J Cereb Blood Flow Metab. 2018; 39(11):2157-2171.

PMID: 29890880 PMC: 6827113. DOI: 10.1177/0271678X18783653.


HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.

Mirzapoiazova T, Mambetsariev N, Lennon F, Mambetsariev B, Berlind J, Salgia R Front Oncol. 2015; 5:164.

PMID: 26258071 PMC: 4508840. DOI: 10.3389/fonc.2015.00164.


Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke.

Wu F, Catano M, Echeverry R, Torre E, Haile W, An J J Neurosci. 2014; 34(43):14219-32.

PMID: 25339736 PMC: 4205548. DOI: 10.1523/JNEUROSCI.5309-13.2014.


The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.

Margheri F, Luciani C, Taddei M, Giannoni E, Laurenzana A, Biagioni A Oncotarget. 2014; 5(6):1538-53.

PMID: 24681666 PMC: 4039230. DOI: 10.18632/oncotarget.1754.